Illumina unveiled BioInsight, a new business unit offering to run large, sequencing‑intensive experiments for pharma and retain data ownership to create reusable datasets. CEO Jacob Thaysen framed the service as a way to accelerate projects like Perturb‑seq screens and supply curated data products and algorithms to drug developers. Thaysen said Perturb‑seq experiments can cost tens of millions and that Illumina will provide development, limited exclusivity, then broader reuse—fuel for AI models. Industry peers Ginkgo and Twist are likewise expanding curated data services for model training and discovery. The move signals a shift from reagent sales toward recurring data and analytics revenue, raising questions about data exclusivity, collaboration terms, and how pharma partners will balance access with the need for proprietary advantage. Perturb‑seq is a single‑cell CRISPR perturbation profiling method that links gene perturbations to transcriptomic effects.